Skip to main content
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1976 Aug;3(4):627–632. doi: 10.1111/j.1365-2125.1976.tb04886.x

Factors influencing the absorption and disposition of mecillinam and pivmecillinam in man

J Andrews, M J Kendall, M Mitchard
PMCID: PMC1428919  PMID: 22216505

Abstract

1 In a pharmacokinetic study in six volunteers peak serum mecillinam concentrations were proportional to the oral dose of pivmecillinam at two dose levels of 200 and 400 mg.

2 Effects of bed rest, probenecid and a 6 day course of treatment with pivmecillinam on serum mecillinam concentrations after an oral dose of pivmecillinam (two 200 mg capsules) have been investigated.

3 Resting subjects had lower peak serum levels and a decreased rate of clearance than moderately active subjects, changes which are similar to those previously reported for benzylpenicillin.

4 Pretreatment with probenecid produced significantly higher serum mecillinam levels, a longer serum antibiotic half-life and a decreased rate of drug clearance which suggests that mecillinam is actively excreted by kidney tubules.

5 Plasma mecillinam level profiles obtained after the first dose of a 6 day treatment period were not significantly different from corresponding values after the first dose on the seventh day which indicates that each dose of mecillinam is eliminated in healthy young adults before succeeding doses are taken.

Full text

PDF
627

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Engberg-Pedersen H. Empirical equation for pharmacokinetic analysis of drug serum levels after oral application. Antimicrob Agents Chemother. 1974 Nov;6(5):554–562. doi: 10.1128/aac.6.5.554. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Greenwood D., Brooks H. L., Gargan R., O'Grady F. Activity of FL 1060, a new beta-lactam antibiotic, against urinary tract pathogens. J Clin Pathol. 1974 Mar;27(3):192–197. doi: 10.1136/jcp.27.3.192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Jordan M. C., de Maine J. B., Kirby W. M. Clinical pharmacology of pivampicillin as compared with ampicillin. Antimicrob Agents Chemother (Bethesda) 1970;10:438–441. [PubMed] [Google Scholar]
  4. Levy G. Effect of bed rest on distribution and elimination of drugs. J Pharm Sci. 1967 Jul;56(7):928–929. doi: 10.1002/jps.2600560739. [DOI] [PubMed] [Google Scholar]
  5. Lund F., Tybring L. 6 -amidinopenicillanic acids--a new group of antibiotics. Nat New Biol. 1972 Apr 5;236(66):135–137. doi: 10.1038/newbio236135a0. [DOI] [PubMed] [Google Scholar]
  6. Park J. T., Burman L. FL-1060: a new penicillin with a unique mode of action. Biochem Biophys Res Commun. 1973 Apr 16;51(4):863–868. doi: 10.1016/0006-291x(73)90006-5. [DOI] [PubMed] [Google Scholar]
  7. Roholt K., Nielsen B., Kristensen Pharmacokinetic studies with mecillinam and pivmecillinam. Chemotherapy. 1975;21(3-4):146–166. doi: 10.1159/000221856. [DOI] [PubMed] [Google Scholar]
  8. Williams J. D., Andrews J., Mitchard M., Kendall M. J. Bacteriology and pharmacokinetics of the new amidino penicillin-mecillinam. J Antimicrob Chemother. 1976 Mar;2(1):61–69. doi: 10.1093/jac/2.1.61. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES